Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply

Detaylı Bibliyografya
Asıl Yazarlar:	Jr, W, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2012

Benzer Materyaller

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Yazar:: Wells, SA, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Reply to J.-F. Chatal et al.
Yazar:: Wells Jr, SA, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
Yazar:: Nils Degrauwe, ve diğerleri
Baskı/Yayın Bilgisi: (2012-06-01)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
Yazar:: Hari Deshpande, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Calcitonin receptor expression in medullary thyroid carcinoma
Yazar:: Virginia Cappagli, ve diğerleri
Baskı/Yayın Bilgisi: (2017-09-01)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer
Yazar:: Ecem Bostan, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
Yazar:: Fallahi P, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
Yazar:: А. М. Mudunov, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

CALCITONINS ROLE - REPLY
Yazar:: Kanis, J, ve diğerleri
Baskı/Yayın Bilgisi: (1977)

Metastatic Medullary Thyroid Carcinoma with Normal Serum Calcitonin Levels
Yazar:: Tania Tofail, MRCP, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Yazar:: Mijin Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Serum calcitonin negative Medullary thyroid carcinoma
Yazar:: Welsing Ellen, ve diğerleri
Baskı/Yayın Bilgisi: (2006-12-01)

Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib
Yazar:: Sravanthi Sanivarapu, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
Yazar:: Ai Matsui, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

In-situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma.
Yazar:: Boultwood, J, ve diğerleri
Baskı/Yayın Bilgisi: (1990)

Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma
Yazar:: Wenliang Yue, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
Yazar:: Heymach, J, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
Yazar:: Pierpaolo Trimboli, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Kinase inhibitors for advanced medullary thyroid carcinoma
Yazar:: Martin Schlumberger, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin
Yazar:: Bo Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

The role of calcitonin in the preoperative stage as the predictor of medullary thyroid cancer metastases
Yazar:: Volodymyr Palamarchuk, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence?
Yazar:: Huguet, I, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Early calcitonin levels in medullary thyroid carcinoma: Prognostic role in patients without distant metastases at diagnosis
Yazar:: Clotilde Sparano, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
Yazar:: LI Rui, LIU Zhuoran, YAN Jiqi
Baskı/Yayın Bilgisi: (2022-06-01)

Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma
Yazar:: Fengli Guo, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
Yazar:: Il Youb Jeong, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer
Yazar:: Yingtong Hou, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Cytodiagnosis of medullary carcinoma thyroid- role of FNAC and serum calcitonin- A case report
Yazar:: Majed B Momin, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

False positive results using calcitonin as a screening method for medullary thyroid carcinoma
Yazar:: Rafael Loch Batista, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Yazar:: Claudio Gambardella, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma
Yazar:: Hyunju Park, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Nephrotic Syndrome as a Complication of Systemic Calcitonin Amyloidosis From Long-Standing Metastatic Medullary Thyroid Cancer
Yazar:: Samantha M. Siskind, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study
Yazar:: Zan Jiao, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Yazar:: Hanrahan, E, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Calcitonin testing in patients with thyroid nodules for screening medullary thyroid carcinoma: a “gray zone”
Yazar:: N. V. Severskaya, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Selective use of vandetanib in the treatment of thyroid cancer
Yazar:: Fallahi P, ve diğerleri
Baskı/Yayın Bilgisi: (2015-07-01)

Biophysical and computational characterization of vandetanib–lysozyme interaction
Yazar:: Kabir, Md Zahirul, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
Yazar:: Abdul Qadir, MPhil, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
Yazar:: Jade Cury-Martins, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Measurement of calcitonin and cea in the needle washout fluid from thyroid nodule for the diagnosis of medullary thyroid carcinoma
Yazar:: N. V. Severskaya, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)